[go: up one dir, main page]

BRPI0707958B8 - composição e kit para testar condições mentais por uma análise de regressão logística e método de medição de condições mentais - Google Patents

composição e kit para testar condições mentais por uma análise de regressão logística e método de medição de condições mentais

Info

Publication number
BRPI0707958B8
BRPI0707958B8 BRPI0707958A BRPI0707958A BRPI0707958B8 BR PI0707958 B8 BRPI0707958 B8 BR PI0707958B8 BR PI0707958 A BRPI0707958 A BR PI0707958A BR PI0707958 A BRPI0707958 A BR PI0707958A BR PI0707958 B8 BRPI0707958 B8 BR PI0707958B8
Authority
BR
Brazil
Prior art keywords
agent
fatigue
mental conditions
stress
testing
Prior art date
Application number
BRPI0707958A
Other languages
English (en)
Inventor
Sekiyama Atsuo
Original Assignee
Sekiyama Atsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekiyama Atsuo filed Critical Sekiyama Atsuo
Publication of BRPI0707958A2 publication Critical patent/BRPI0707958A2/pt
Publication of BRPI0707958B1 publication Critical patent/BRPI0707958B1/pt
Publication of BRPI0707958B8 publication Critical patent/BRPI0707958B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/306—Chronic fatigue syndrome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

agente indicador e agente para testar estresse, fadiga e condições/distúrbios mentais, método de medição das referidas doenças e kit para testar condições/distúrbios mentais a presente invenção refere-se a técnicas que são capazes de avaliar objetivamente e especificamente várias condições mentais ou físicas, das quais a avaliação foi convencionalmente possível somente por métodos dependentes de sintomas subjetivos, tais como estresse e fadiga. e especificamente descrito um agente indicador de estresse ou fadiga incluindo pelo menos dois fatores selecionados do grupo consistindo em il-1 (beta), il-1ra, il-2, il-3, il-4, il-5, il-6, il-7, il-8, il-9, il-10, il-11, il-12, il-13, il-15, il-17, il- 18, fotaxina, fgf básico, g-csf, gm-csf, ifn-y, ifn-(alfa), ip-10, mcp-1, mip-lcx, mip-1(beta), pdgf-bb, rantes, tnf-(alfa), vegf, csf-2, tgf-(beta), neurotrofina 5, mcp-3, (beta)-2-microglobulina, angiotensina ii, csf-3, ligante de quimiocina cxc 1, ligante de quimiocina cxc 5 e hgf; um agente para testar estresse ou fadiga incluindo pelo menos duas moléculas selecionadas do grupo consistindo em moléculas que reconhecem especificamente os fatores, respectivamente; um método de medição de estresse ou fadiga com o agente de teste; e um agente indicador para avaliar a intensidade das condições ou distúrbios mentais, incluindo pelo menos dois fatores selecionados do grupo do fator, em que cada um dos fatores é pesado.
BRPI0707958A 2006-02-17 2007-02-16 composição e kit para testar condições mentais por uma análise de regressão logística e método de medição de condições mentais BRPI0707958B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006-041633 2006-02-17
JP2006041633 2006-02-17
PCT/JP2007/052887 WO2007094472A1 (ja) 2006-02-17 2007-02-16 生体負荷の指標剤および生体負荷の測定方法

Publications (3)

Publication Number Publication Date
BRPI0707958A2 BRPI0707958A2 (pt) 2011-05-17
BRPI0707958B1 BRPI0707958B1 (pt) 2018-10-16
BRPI0707958B8 true BRPI0707958B8 (pt) 2021-07-27

Family

ID=38371648

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707958A BRPI0707958B8 (pt) 2006-02-17 2007-02-16 composição e kit para testar condições mentais por uma análise de regressão logística e método de medição de condições mentais

Country Status (20)

Country Link
US (1) US20100233818A1 (pt)
EP (2) EP2006680B1 (pt)
JP (1) JP5069213B2 (pt)
KR (1) KR101473495B1 (pt)
CN (1) CN101454669B (pt)
AU (1) AU2007215739B2 (pt)
BR (1) BRPI0707958B8 (pt)
CA (1) CA2642706C (pt)
CY (1) CY1115418T1 (pt)
DK (1) DK2006680T3 (pt)
ES (1) ES2474690T3 (pt)
HR (1) HRP20140673T1 (pt)
IL (1) IL193496A (pt)
MY (1) MY151424A (pt)
NZ (1) NZ571018A (pt)
PL (1) PL2006680T3 (pt)
PT (1) PT2006680E (pt)
RU (1) RU2519324C2 (pt)
SI (1) SI2006680T1 (pt)
WO (1) WO2007094472A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
CA2717763A1 (en) * 2008-03-04 2009-09-11 John Bilello Diagnosing and monitoring depression disorders based on multiple biomarker panels
EP2272044A4 (en) * 2008-03-12 2011-07-06 Ridge Diagnostics Inc INFLAMMATORY BIOMARKING FOR MONITORING DEPRESSION DISEASES
JP5219048B2 (ja) * 2008-09-17 2013-06-26 独立行政法人農業・食品産業技術総合研究機構 抗豚インターロイキン−１８抗体を用いた動物のストレス評価方法
WO2010045490A2 (en) * 2008-10-15 2010-04-22 Ridge Diagnostics, Inc. Human biomarker hypermapping for depressive disorders
JP5767973B2 (ja) * 2008-11-18 2015-08-26 リッジ ダイアグノスティックス，インコーポレイテッド 大うつ病性障害のためのメタボリック症候群バイオマーカーおよびｈｐａ軸バイオマーカー
US20100280760A1 (en) * 2009-04-01 2010-11-04 Ridge Diagnostics, Inc. Biomarkers for monitoring treatment of neuropsychiatric diseases
CN102460153A (zh) * 2009-04-06 2012-05-16 里奇诊断学股份有限公司 监控神经精神疾病治疗的生物标记
JP4717962B2 (ja) * 2009-04-14 2011-07-06 片倉工業株式会社 慢性ストレスの評価方法
JP5553525B2 (ja) * 2009-04-17 2014-07-16 敦生 関山 生体負荷の指標剤および生体負荷の測定方法
JP5744063B2 (ja) * 2010-01-26 2015-07-01 リッジ ダイアグノスティックス，インコーポレイテッド うつ病の疾患重症度を層別化するためおよび処置をモニタリングするための複数のバイオマーカーパネル
JP5821447B2 (ja) * 2011-09-13 2015-11-24 大正製薬株式会社 カルジオリピンを用いた疲労の判定方法
JP2016500825A (ja) * 2012-10-24 2016-01-14 ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング／ビジネス／アズ キャロライナズ ヘルスケア システム 肝臓障害を特定するためのバイオマーカー
JP5710666B2 (ja) * 2013-02-25 2015-04-30 敦生 関山 生体負荷の指標剤および生体負荷の測定方法
JP6205175B2 (ja) * 2013-05-16 2017-10-04 株式会社Ｒｅｓｖｏ 精神・神経疾患バイオマーカー
CA3112130A1 (en) * 2013-07-11 2015-01-15 University Of North Texas Health Science Center At Fort Worth Blood-based screen for detecting neurological diseases in primary care settings
US11885816B2 (en) 2013-11-26 2024-01-30 University Of North Texas Health Science Center At Forth Worth Personalized medicine approach for treating cognitive loss
WO2015174544A1 (ja) * 2014-05-16 2015-11-19 国立研究開発法人国立精神・神経医療研究センター 精神疾患判定マーカー
WO2017062568A1 (en) * 2015-10-08 2017-04-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Biomarkers for diagnosing post traumatic stress disorder
CN106814145B (zh) * 2016-12-20 2019-08-30 河北工程大学 一种人体疲劳测定方法
RU2630605C1 (ru) * 2017-01-09 2017-09-11 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью Способ оценки риска нарушения здоровья работников титано-магниевого производства, режим труда которых включает ночные смены
CN106706929B (zh) * 2017-01-22 2019-01-18 河北工程大学 一种利用唾液检测人体疲劳的方法
CN108333362B (zh) * 2017-12-21 2021-04-02 河北工程大学 一种人体疲劳测定方法
CA3088512C (en) 2018-01-18 2023-09-19 University Of North Texas Health Science Center At Fort Worth Companion diagnostic for nsaids and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease
WO2020241809A1 (ja) * 2019-05-31 2020-12-03 日本たばこ産業株式会社 幸福感の評価方法及び幸福感を評価するためのデータ取得方法
CN112716505A (zh) * 2020-12-08 2021-04-30 河北工程大学 一种快速的疲劳检测方法
CN113180595A (zh) * 2021-03-25 2021-07-30 河北工程大学 基于人体唾液蛋白测定重点行业职业疲劳程度的检测系统
CN113151443B (zh) * 2021-04-16 2022-07-01 中央民族大学 细胞因子联合分析作为精神分裂症标志物及其应用
JP7767055B2 (ja) * 2021-08-16 2025-11-11 株式会社Ｌｓｉメディエンス 精神ストレスの定量法
KR102530616B1 (ko) * 2022-09-22 2023-05-10 주식회사 메디푸드플랫폼 의과학 및 성분학 기반의 정신 상태 분석 장치, 방법 및 프로그램

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JP4004088B2 (ja) * 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
JP2724987B2 (ja) * 1994-11-15 1998-03-09 株式会社林原生物化学研究所 インターフェロン−γの産生を誘導するポリペプチド
JP2952750B2 (ja) * 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
JP4490576B2 (ja) * 1999-10-26 2010-06-30 富山化学工業株式会社 中枢神経系作用薬のスクリーニング方法及びストレス状態の評価方法
JP2005500847A (ja) * 2001-08-24 2005-01-13 アドバンスド セル テクノロジー、インコーポレイテッド 分化誘導薬の同定のためのスクリーニング検定及び細胞治療用の分化細胞の調製
ES2442615T5 (es) * 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
US20050084880A1 (en) * 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions
JP2005124565A (ja) * 2003-09-29 2005-05-19 Sogo Ikagaku Kenkyusho:Kk 新規神経ペプチド及びその利用
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
US20050208519A1 (en) * 2004-03-12 2005-09-22 Genenews Inc. Biomarkers for diagnosing schizophrenia and bipolar disorder
AU2005258569B2 (en) 2004-06-30 2012-05-03 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use thereof
JP4645939B2 (ja) 2004-07-22 2011-03-09 日本電気株式会社 移動基地局位置決定システム、端末位置決定システム、移動基地局、無線端末及び基地局位置決定プログラム

Also Published As

Publication number Publication date
NZ571018A (en) 2012-03-30
JPWO2007094472A1 (ja) 2009-07-09
WO2007094472A1 (ja) 2007-08-23
CN101454669A (zh) 2009-06-10
MY151424A (en) 2014-05-30
AU2007215739B2 (en) 2014-01-16
ES2474690T3 (es) 2014-07-09
RU2008137234A (ru) 2010-03-27
RU2519324C2 (ru) 2014-06-10
SI2006680T1 (sl) 2014-08-29
BRPI0707958A2 (pt) 2011-05-17
JP5069213B2 (ja) 2012-11-07
KR20090007289A (ko) 2009-01-16
EP2006680A4 (en) 2009-09-09
CY1115418T1 (el) 2017-01-04
HRP20140673T1 (hr) 2014-10-10
IL193496A (en) 2015-07-30
DK2006680T3 (da) 2014-06-23
PT2006680E (pt) 2014-07-14
AU2007215739A1 (en) 2007-08-23
EP2453236A2 (en) 2012-05-16
BRPI0707958B1 (pt) 2018-10-16
CA2642706C (en) 2017-08-01
CN101454669B (zh) 2013-11-20
IL193496A0 (en) 2009-05-04
EP2453236A3 (en) 2012-08-22
HK1133461A1 (en) 2010-03-26
KR101473495B1 (ko) 2014-12-17
US20100233818A1 (en) 2010-09-16
CA2642706A1 (en) 2007-08-23
EP2006680A1 (en) 2008-12-24
EP2006680B1 (en) 2014-04-16
PL2006680T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
BRPI0707958B8 (pt) composição e kit para testar condições mentais por uma análise de regressão logística e método de medição de condições mentais
Sakurai et al. Serum Metabolic Profiles of the Tryptophan-Kynurenine Pathway in the high risk subjects of major depressive disorder
Verber et al. Biomarkers in motor neuron disease: a state of the art review
Fu et al. Serum inflammatory cytokines levels and the correlation analyses in Parkinson’s disease
Van Kesteren et al. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies
Liu et al. Elevated levels of IFN-γ in CSF and serum of patients with amyotrophic lateral sclerosis
Chang et al. Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model
Lee et al. Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis
Runfola et al. Body dissatisfaction in women across the lifespan: Results of the UNC‐SELF and gender and body image (GABI) studies
Umemura et al. Baseline plasma C-reactive protein concentrations and motor prognosis in Parkinson disease
Zou et al. Cognitive function and plasma BDNF levels among manganese-exposed smelters
da Silva et al. Inflammation and internalizing disorders in adolescents
Zaaroura et al. Biomarkers in alopecia Areata: A systematic review and meta-analysis.
Shaddox et al. Localized aggressive periodontitis immune response to healthy and diseased subgingival plaque
Miyauchi et al. Effect of antidepressant treatment on plasma levels of neuroinflammation‐associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region
Yamashita et al. Significant CMAP decrement by repetitive nerve stimulation is more frequent in median than ulnar nerves of patients with amyotrophic lateral sclerosis
Rudick et al. Understanding the pathophysiology behind chairside diagnostics and genetic testing for IL‐1 and IL‐6
Yasar et al. Sprint interval training (SIT) reduces serum epidermal growth factor (EGF), but not other inflammatory cytokines in trained older men
Pinilla et al. Increased synthesis of pro-inflammatory cytokines in C9ORF72 patients
Garcia-Alvarez et al. Differential blood-based biomarkers of psychopathological dimensions of schizophrenia
Pola et al. Exploring inflammation‐related protein expression and its relationship with TSPO PET in Alzheimer's disease
Bock et al. Temperament traits moderate the relationship between Childhood Trauma and Interleukin 1β profile in young adults
Roberson et al. Cytokine and chemokine alterations in Down syndrome
RU2017138974A (ru) Прогностические биомаркеры клинического ответа на лечение анти-лпс иммуноглобулином
Schmidt et al. Stress-related hormones in association with periodontal condition in adolescents—results of the epidemiologic LIFE Child study

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2155 DE 24/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.